Q4 2021 Results
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
Financial performance
Innovation: Pipeline overview
Innovation: Clinical trials
CRM
IHD
Neuroscience
Ophthalmology
Respiratory & Allergy
Oncology: Solid Tumors
Hematology
Biosimilars
Global Health
Abbreviations
MIJ821- NR2B negative allosteric modulator (NAM)
Study
Indication
Phase
Patients
Primary Outcome
Measures
Arms Intervention
NCT04722666 (CMIJ821A12201)
Acute depression
Phase 2
195
Change from baseline to 24 hours in the total score of the Montgomery Åsberg
Depression Rating Scale (MADRS)
MIJ821 (mg/kg) very low dose for 40 minutes IV infusion on Day 1, Day 15 and Day 29
MIJ821 (mg/kg) low dose for 40 minutes IV infusion on Day 1, Day 15 and Day 29
MIJ821 (mg/kg) high dose for 40 minutes IV infusion on Day 1, Day 15 and Day 29
MIJ821 (mg/kg) very high dose for 40 minutes IV infusion on Day 1, Day 15 and Day 29
Placebo 40 minutes IV infusion of 0.9% sodium chloride on Day 1, Day 15 and Day 29
MIJ821 (mg/kg) high dose for 40 minutes IV infusion on Day 1 or 0.9% sodium chloride
Participants who have suicidal ideation with intent
Target Patients
Read-out Milestone(s)
Publication
2023
TBD
95 Investor Relations | Q4 2021 Results
NOVARTIS | Reimagining MedicineView entire presentation